Bonifen (Pyritinol)

Quick links

Choose a section

Quick links to important sections

Advertisements

Bonifen (Pyritinol)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Bonifen (Pyritinol)

Property Description
Active ingredient Pyritinol (Pyridoxine disulfide)
Form Oral tablets, oral solution
Pharmacological class Nootropic agent (Cerebroactive)
General purpose Supports cognitive function and cerebral metabolism
Origin Synthetic derivative of Vitamin B6

What is Pyritinol (Bonifen) and What Type of Drug is it?

Pyritinol is a synthetic, single-ingredient medication classified as a nootropic agent or cerebroactive drug designed to support functions within the central nervous system. This classification indicates that the medicine is primarily purposed to influence and enhance cognitive performance, distinguishing it from general stimulants or sedatives. The drug entity utilizes Pyritinol as its sole active ingredient, which is chemically a derivative of Pyridoxine (Vitamin B6). Pyritinol is classified among agents used for cerebral function disorders. This indicates its role in supporting the overall functional efficiency of the brain and establishes it as distinct from purely peripheral metabolic enhancers.

Composition, Origin, and Available Forms

Pyritinol is a synthetic compound, meaning it is manufactured in a laboratory, specifically derived from the essential micronutrient Vitamin B6. The chemical synthesis results in Pyridoxine disulfide, reflecting the structural linkage that allows it to effectively cross the blood-brain barrier—an action intended to ensure its neurotropic effect. The primary dosage forms are intended for oral administration, typically including film-coated tablets and an oral solution. This choice of forms, unlike injections or topical applications, underscores its systemic use for central nervous system support. It is characterized as a neuroprotector with metabolic activity.

General Purpose: How Pyritinol Supports Cognitive Function

The general purpose of Pyritinol is to support and stabilize overall brain performance by enhancing cerebral metabolism. This nootropic agent helps nerve cells utilize glucose, the brain's critical energy source, thereby augmenting the energy available for cognitive tasks. This fundamental action is intended to help relieve symptoms associated with generalized cognitive impairment, such as difficulties with concentration and mental fatigue. For instance, it is typically used in scenarios where improved mental endurance or sustained attention is needed, such as during periods of high mental demand.

Advertisements

What side effects are possible with Bonifen (Pyritinol)?

Possible side effects and safety information

The safety profile of Pyritinol is defined by regulatory documents which classify possible adverse reactions by frequency and the physiological system affected, providing a structured view of the medicine’s characteristics.


Documented Adverse Reactions

The most frequently reported adverse reactions are often within the Gastrointestinal and Nervous System domains, and are typically classified as Common. These effects include headache, dizziness, nausea, vomiting, and epigastric distress (stomach pain).

Less common presentations may involve Psychiatric Disorders, such as insomnia and restlessness, or skin reactions including pruritus (itching) and skin rash.

Adverse Reaction Type System-Organ Classes Involved
Common Effects Gastrointestinal, Nervous System
Serious & Rare Effects Hepatobiliary, Pancreatic, Immune System

Serious and Rare Safety Considerations

The official safety documents highlight rare but clinically serious adverse reactions. These include severe organ-specific injuries such as acute pancreatitis, severe cholestatic hepatitis (a serious liver condition), and severe forms of skin reaction like photoallergic eruption. These severe events are generally classified within the Rare frequency category in official prescribing information.


Safety Restrictions and Contraindications

Pyritinol use is subject to specific constraints documented in regulatory labeling. The medicine is contraindicated in individuals with a known hypersensitivity or allergy to Pyritinol or its components. It is also contraindicated in patients with severe liver disease and in those with hemochromatosis (a condition involving excessive iron accumulation). Additionally, use is generally not recommended during pregnancy or while breastfeeding due to a lack of sufficient safety data in these populations.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Pyritinol establishes a baseline of low toxicity, drawing from both clinical experience and non-clinical data. Consequently, acute, severe overdose is regarded as unlikely, and government regulatory documents state that no cases of intoxication have been reported to date.

Entity Official Regulatory Statement
Documented Manifestations Potential central nervous system over-excitability, specifically documented as states of agitation.
Severity Classification Officially defined as low toxicity.
Antidote Status No specific antidote is listed in the official regulatory information.

When to Seek Help and Required Actions

If signs of CNS over-excitability, such as states of agitation, should occur, the regulatory mandate is to seek medical attention. The official procedure required by regulatory authorities for managing a potential overdose is the application of general symptomatic therapeutic guidelines. This approach focuses solely on supportively treating the documented manifestation. The regulatory information does not specify population-based considerations (e.g., pediatric or renal impairment) or special monitoring requirements within the context of an overdose.

Advertisements

Therapeutic Uses of Bonifen (Pyritinol)

What Bonifen (Pyritinol) Treats: Main Uses and Benefits

Pyritinol is categorized as an agent relevant for managing symptoms associated with cerebrovascular and cognitive disorders. It is typically utilized to help with symptoms related to cognitive strain, such as memory loss, difficulties with concentration, and symptoms of mental fatigue.

The medication is utilized in clinical settings involving conditions characterized by periods of heightened symptoms, such as dementia syndromes and age-related cognitive decline, as well as in supportive therapy for sequelae of brain injury or cerebrovascular events. It is also considered relevant for managing symptoms that interfere with daily functioning in the context of certain learning challenges in children. Supportive therapy is intended to help maintain a sense of stability when symptoms are more noticeable and assist with maintaining functional stability.


Quick Fact: Symptomatic Support for Mental Fatigue

Pyritinol may be part of symptomatic management to help support certain aspects of cognitive function in older adults and generally assists with maintaining the capacity for mental effort, contributing to easing the overall symptom load associated with mental decline.

Advertisements

Eligibility and Restrictions for Use

Pyritinol eligibility is determined by official regulatory documentation, which sets mandatory exclusions (contraindications) and conditional use requirements.

Contraindicated Populations

Use is strictly prohibited in individuals with a known hypersensitivity to Pyritinol or its components. The medicine is also contraindicated in patients with certain severe pre-existing conditions, including: active peptic ulcers, severe disorders of liver function, pre-existing kidney damage, severe changes in the blood count, and a history of autoimmune diseases (such as lupus erythematosus) [1.2, 1.3, 3.4].

Conditional Use and Restrictions

  • Pregnancy and Lactation: Use during pregnancy or while breastfeeding is not recommended unless a physician determines that the potential benefits clearly outweigh the risks [1.1, 2.1].
  • Organ Function: Patients with non-severe liver diseases or kidney disorders should use the medicine with caution [1.1].
  • Rheumatoid Arthritis: Individuals with rheumatoid arthritis may require regular clinical check-ups and laboratory monitoring due to a noted increased sensitivity [2.1].
  • Excipient Intolerance: Specific formulations may be contraindicated in patients with conditions like known fructose intolerance (oral solution) due to excipient content [3.4].

Age-Group Eligibility

The medicine is documented for use across a broad age range. Its use is established in adults and older adults for cognitive conditions and in pediatric populations (children and adolescents) for certain learning disorders [3.3].

Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bonifen (Pyritinol)

This section summarizes the official interaction profile based strictly on a review of publicly accessible government regulatory documentation, such as Summaries of Product Characteristics (SmPC) from European national health agencies and monographs from other international authorities. The analysis indicates that a published, formally classified interaction section is currently not available in these key regulatory sources.

Interaction scope

Category Finding Based on Accessible Regulatory Documents
Medicinal product categories with documented interactions No specific drug or product categories are explicitly listed as interacting with Pyritinol in the official regulatory labels reviewed.
Specific interacting medicines (if explicitly listed) No individual co-administered medicines that would mandate dose modification or require monitoring are explicitly listed in accessible regulatory labels.
Mechanistic basis of interactions (only if stated in label) No documented mechanistic basis, such as inhibition or induction of specific Cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp), is stated in accessible regulatory labels.
Timing-based interaction rules (if applicable) No mandatory timing or separation requirements are documented due to an interaction.
Population-specific interaction notes (if applicable) No interaction notes specific to a patient population (e.g., hepatic impairment) are documented in the context of co-administered medicines.
Interaction-related restrictions No formal "do-not-combine" rules or restrictions are documented based on an interaction.

Interaction classifications (high-level)

Classification Finding Based on Accessible Regulatory Documents
Interaction severity classification (as defined in official documents) Not classified. No specific interaction is documented in accessible regulatory labels.
Regulatory basis (EMA / FDA / etc.) Information derived from government drug regulatory documents reviewed, which indicate an absence of a published, classified interaction profile.
Interaction-context constraints (as defined in official documents) None defined. No officially documented constraints related to co-administration or product use timing.

Resulting interaction structure

Official interaction statements:

  • No specific drug–drug interactions are formally documented in the publicly accessible prescribing information provided by authoritative government regulatory agencies.
  • No specific pharmacokinetic or pharmacodynamic interactions, including those involving food, alcohol, or supplements, are explicitly stated in the official regulatory labels reviewed.
  • No officially stated constraints exist regarding the co-administration of Pyritinol with other therapies or products.

Connection to the overall interaction profile (2–4 sentences):

This lack of explicit documentation defines the official interaction structure, confirming that no mandatory timing rules, contraindicated combinations, or exposure-altering effects are officially specified in the publicly accessible regulatory labels. The drug's regulatory profile regarding co-administration is therefore characterized by the absence of published, official interaction restrictions.

Advertisements

Mechanism of Action

Pyritinol is a disulfide-linked derivative of pyridoxine (vitamin B6) that crosses the blood-brain barrier. Its primary mechanism involves modulation of several neurotransmitter systems, with selective accumulation in cerebral tissue.

The compound enhances cholinergic signaling by increasing the activity of choline acetyltransferase and facilitating the high-affinity uptake of choline into presynaptic neurons, resulting in elevated cortical acetylcholine release. Downstream, this activation of the cholinergic system in the cortex is associated with an increase in cyclic GMP (cGMP) levels.

Simultaneously, pyritinol functions as an inhibitor or antagonist at other central nervous system targets. It non-competitively reduces the affinity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) for its receptors in areas including the cerebral cortex, striatum, and cerebellum. This diminished GABAergic affinity leads to a functional disinhibition of neuronal activity.

Furthermore, pyritinol is observed to increase glucose utilization and exhibit antioxidant properties within the brain. The net system-level consequence is the widespread activation and modulation of key neuronal circuits.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Bonifen (Pyritinol)

The administration of Pyritinol follows standardized therapeutic protocols. The medication is available for oral use in the form of tablets, often 100 mg or 200 mg units, or as an oral solution.

Administration Scope

Feature Official Instruction / Rule
Route of administration Oral (by mouth).
Standard Adult Daily Dose A total daily dose commonly ranges from 300 mg up to 600 mg of the active substance.
Frequency and Schedule The total dose is typically administered in three divided doses (t.i.d.) throughout the day.
Intake Condition The medicine is generally advised to be taken with food or following a meal.
Age-Group Rule A specific, lower daily dosage is often designated for children and adolescents, such as 300 mg per day.
Procedural Condition Tablets are intended to be swallowed whole with water and are not to be crushed, chewed, or broken.

Resulting Procedural Structure

The established protocol defines the sequence for using the medication. The process involves the single dose being taken orally and with food, with this sequence repeated to meet the three times daily frequency. This structured approach, including the requirement to swallow tablets whole, is designed to support consistent application of the medication.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bonifen (Pyritinol)

Pyritinol was studied to explore measured outcomes related to cognitive function in several types of clinical trials. The research aims to understand the patterns observed when Pyritinol was studied alongside measured changes in cognitive measures and symptoms, highlighting what is known and what is still uncertain about the overall evidence landscape.


Evidence for Primary Cognitive Indications

Research has primarily involved Randomized Controlled Trials (RCTs) and systematic reviews. In older adults with mild to moderate cognitive impairment and dementia syndromes, studies evaluated how Pyritinol was associated with measured cognitive scores, functional ratings, and behavioral symptoms. Findings describe patterns observed in these trials, but when synthesized into systematic reviews, the results were often cited as mixed or inconsistent, suggesting variability in measured responses between patient groups and studies.


Research in Other Populations and Limitations

Pyritinol was also explored in patients experiencing the sequelae of brain injury or dealing with cerebrovascular events, typically in short-term clinical trials examining outcomes related to general clinical status. For pediatric populations with learning challenges, controlled trials were evaluated, but findings were inconsistent. A long-term RCT in infants with severe developmental issues reported that Pyritinol was not found to be useful for measured neurodevelopmental indices in that specific population.

Long-term effects are not fully established. Clinical trials primarily focus on short-term symptom changes (e.g., 6 to 12 weeks), and there is limited information regarding the sustained changes or durability of any measured effects over multiple years. Certainty remains low for broad conclusions due to small sample sizes in many older trials and the inconsistent nature of the findings across the published evidence.

Key Studies & References

  1. Nootropics for dementia: An umbrella review (Used to establish context on mixed evidence and general class limitations)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bonifen (Pyritinol) (FAQ)


Q: Is Bonifen classified as a nootropic medicine?

A: Official regulatory documents confirm that Pyritinol is classified as a nootropic agent or a cerebroactive drug. This classification indicates the medicine is intended to influence or support functions within the central nervous system related to cognitive performance.


Q: Can Bonifen cause sleep disturbances, such as insomnia or restlessness?

A: Official product information lists insomnia (difficulty sleeping) and restlessness as documented adverse effects of Bonifen. These effects are typically classified under Psychiatric Disorders in regulatory safety summaries.


Q: Can Bonifen potentially cause changes in mood or increased excitability?

A: According to official regulatory information, increased excitability is listed as an uncommon adverse effect. This potential effect is classified within the psychiatric disorders category in the drug's safety profile.


Q: Does Bonifen have any restrictions for patients with known peptic ulcers?

A: Official documents state that Bonifen is contraindicated, meaning its use is strictly prohibited, for individuals with pre-existing conditions, including active peptic ulcers. This exclusion is detailed in the official safety information.


Q: Can Bonifen be taken simultaneously with common CNS stimulant medications?

A: The official regulatory labels state that no specific drug-drug interactions are formally documented. This includes interactions with other central nervous system (CNS) stimulant medications.


Q: Is there an interaction between Bonifen and products containing caffeine?

A: Official regulatory information indicates that no specific pharmacokinetic or pharmacodynamic interactions, including those involving food or supplements like caffeine, are explicitly stated.


Q: Has Bonifen been studied for its potential antioxidant properties?

A: The official description of how the medicine works notes that it is observed to exhibit an antioxidant effect within the brain. However, regulatory documents do not cite specific studies or indications based solely on this property.


Q: Does Bonifen affect iron levels in the body for people with conditions like hemochromatosis?

A: Official documents state that Bonifen is contraindicated for people with hemochromatosis (a condition of excessive iron accumulation). This restriction is in place because the medicine may increase the absorption of iron in the gastrointestinal tract.


Q: Is there substantial research evidence supporting Bonifen's use in dementia syndromes?

A: Studies have examined the medicine in randomized trials for dementia syndromes. However, when these trials are synthesized into systematic reviews cited in official documents, the findings are often characterized as mixed or inconsistent.


Q: Why is Bonifen sometimes referred to as 'Pyrithioxine'?

A: Regulatory and scientific documents confirm that the active ingredient, Pyritinol, is also known by the synonym Pyrithioxine. Its full chemical name is Pyridoxine disulfide, reflecting its structural relationship to Vitamin B6.


Q: Is Bonifen generally considered an over-the-counter medication or a prescription-only drug?

A: The regulatory status of Bonifen can vary depending on the country. Regulatory records indicate that the medicine has been sold as both a prescription drug and an over-the-counter (OTC) drug in different global regions over time.


Q: What are the signs of an allergic reaction to Bonifen that I should be aware of?

A: Official regulatory information notes that signs of an allergic reaction include various forms of rashes of the skin and pruritus (itching). Pyrexia (a noted increase in body temperature) is also noted as a possible sign of these adverse reactions.


Q: Is there a need for monitoring liver function while taking Bonifen?

A: Bonifen is contraindicated in cases of severe liver disease, and liver function disorders are documented as a potential side effect. Regulatory documents indicate caution is advised; however, specific routine monitoring schedules for non-severe patients are generally not explicitly detailed in the accessible regulatory summaries.


Q: Is there an increased risk of side effects if I have rheumatoid arthritis?

A: Official regulatory warnings indicate that patients with rheumatoid arthritis show a greater tendency to develop undesirable effects. This is due to a noted increased sensitivity to Pyritinol in this population.


Q: Can Bonifen affect my blood pressure or heart rate?

A: Official adverse reaction documents list common effects such as headache and dizziness. However, no specific changes to blood pressure or heart rate are explicitly listed as documented adverse effects within the cardiovascular system organ class.


Q: What kinds of skin reactions have been reported with Bonifen use?

A: Documented skin reactions include general rashes and pruritus (itching). Official safety information also reports rare and very rare but severe forms, such as lichen planus and bullous pemphigoid.


Q: What is the professional guidance on consuming alcohol while taking Bonifen?

A: While no specific drug-alcohol interaction is formally documented in regulatory labels, the general professional advice is to exercise caution or to limit alcohol consumption as a precautionary measure during use.


Q: Is an interaction possible between Bonifen and medications similar to D-penicillamine?

A: Official regulatory information indicates that due to the chemical relationship between Pyritinol and D-penicillamine, patients with a known hypersensitivity to D-penicillamine may experience similar adverse effects when using Bonifen.


Q: What type of research has been done on Bonifen's use after a stroke?

A: Research has focused on short-term clinical trials involving patients dealing with the sequelae of brain injury or those who have experienced cerebrovascular events (like stroke). These trials typically examine outcomes related to general clinical status.


Q: Does Bonifen contain any steroids?

A: The official composition describes Bonifen as a synthetic derivative of Vitamin B6 (pyridoxine). It is classified as a nootropic agent and does not contain any steroid compounds.


Q: Can Bonifen be used simply to enhance mental focus in healthy individuals?

A: The official general purpose of this nootropic agent is to support brain performance for the relief of symptoms associated with generalized cognitive impairment. Its purpose is not specified as a medication for the enhancement of mental focus in healthy individuals.


Q: Does Bonifen require any special dietary restrictions?

A: Official regulatory labels state that no specific pharmacokinetic or pharmacodynamic interactions involving food are explicitly stated. This means no special dietary restrictions are officially documented.

Advertisements

How should Bonifen (Pyritinol) be stored and disposed of?

How to Store and Dispose of Bonifen (Pyritinol)?

The storage and disposal of Bonifen (Pyritinol) must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirements

The medicine must be stored in its original container, which must be kept tightly closed. Storage conditions typically require that the product is shielded from light and moisture and stored at or below a controlled room temperature, often specified as 25 C or 30 C. Unless otherwise directed, do not freeze or refrigerate the product. All medicine must be kept out of the sight and reach of children.

️ Disposal Instructions

The most recommended method for discarding unused or expired Bonifen is through an official drug take-back program. If a take-back site is unavailable, the product may be disposed of in household trash by mixing the medicine with an unappealing substance like dirt or used coffee grounds, placing the mixture in a sealed bag, and then discarding it. The drug should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonifen (Pyritinol) found in:

A-Z Index: